High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
78.08B
-8.88%
5.863
-7.52%
76.16B
-2.47%
0.000
-100%
81.15B
+5.59%
0.000
-100%
Estimates Revision
The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -3.49% over the past three months. During the same period, the stock price has changed by -14.52%.
Revenue Estimates for FY2025
Revise Downward
-3.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-8.3%
In Past 3 Month
Stock Price
Go Down
-14.52%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 47.990
Low
47.00
Averages
57.37
High
70.00
Current: 47.990
Low
47.00
Averages
57.37
High
70.00
Morgan Stanley
Thibault Boutherin
Underweight
downgrade
$43 -> $42
2025-12-03
New
Reason
Morgan Stanley
Thibault Boutherin
Price Target
$43 -> $42
2025-12-03
New
downgrade
Underweight
Reason
Morgan Stanley analyst Thibault Boutherin lowered the firm's price target on Novo Nordisk to $42 from $43 and keeps an Underweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Goldman Sachs
Buy
downgrade
$60 -> $54
2025-11-28
Reason
Goldman Sachs
Price Target
$60 -> $54
2025-11-28
downgrade
Buy
Reason
Goldman Sachs lowered the firm's price target on Novo Nordisk to $54 from $60 and keeps a Buy rating on the shares.
BMO Capital
Evan Seigerman
Market Perform
downgrade
$50 -> $46
2025-11-25
Reason
BMO Capital
Evan Seigerman
Price Target
$50 -> $46
2025-11-25
downgrade
Market Perform
Reason
BMO Capital analyst Evan Seigerman lowered the firm's price target on Novo Nordisk to $46 from $50 and keeps a Market Perform rating on the shares. EVOKE/EVOKE misses are negative for sentiment, but larger concerns are evolving for Novo's commercial business heading into 2026, the analyst tells investors in a research note. BMO adds that following its recent conversations with the company, the firm believes that numerous negative headwinds for 2026 - including pricing pressures, further gross-to-net compression, and delayed Medicare/Medicaid uptake - may be underappreciated by analysts.
JPMorgan
Overweight
maintain
2025-11-24
Reason
JPMorgan
Price Target
2025-11-24
maintain
Overweight
Reason
JPMorgan views the 9% selloff in shares of Novo Nordisk after the failure of semaglutide in Alzheimer's as an overreaction. While the news removes a potential upside share driver, there is limited to no impact on Novo forecasts, the analyst tells investors in a research note. JPMorgan keeps an Overweight rating on the shares.
HSBC
Buy
to
Hold
downgrade
DKK 300
2025-11-24
Reason
HSBC
Price Target
DKK 300
2025-11-24
downgrade
Buy
to
Hold
Reason
HSBC downgraded Novo Nordisk to Hold from Buy with a DKK 300 price target.
HSBC
Rajesh Kumar
Buy -> Hold
downgrade
2025-11-24
Reason
HSBC
Rajesh Kumar
Price Target
2025-11-24
downgrade
Buy -> Hold
Reason
HSBC analyst Rajesh Kumar downgraded Novo Nordisk to Hold from Buy with a price target of DKK 300, down from DKK 445. Novo's EVOKE and EVOKE-plus trials did not show superiority over placebo in slowing Alzheimer's progression, removing a key potential driver for offsetting GLP pricing pressures, the analyst tells investors in a research note. Combined with expected 2026 impacts from price declines, generics, and weaker Ozempic trends, growth may be challenging to sustain, and the market may await tangible execution evidence for the obesity segment's volume potential, HSBC says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Novo Nordisk A/S (NVO.N) is 0.00, compared to its 5-year average forward P/E of 27.47. For a more detailed relative valuation and DCF analysis to assess Novo Nordisk A/S 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
27.47
Current PE
0.00
Overvalued PE
35.30
Undervalued PE
19.65
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Undervalued
5Y Average EV/EBITDA
19.86
Current EV/EBITDA
9.62
Overvalued EV/EBITDA
24.53
Undervalued EV/EBITDA
15.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
9.52
Current PS
4.27
Overvalued PS
11.89
Undervalued PS
7.14
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 112.57% over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
NVO News & Events
Events Timeline
(ET)
2025-12-01
07:30:00
BofA Raises Novo Nordisk Price Target to DKK 340 Amid Cautious Outlook
2025-11-25 (ET)
2025-11-25
18:51:35
Medicare Secures 71% Price Reduction on Novo's Ozempic and Wegovy, According to Bloomberg
2025-11-25
16:25:53
Novo Nordisk Experiences Moderate Bullish Momentum as Shares Rise 4.61%
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/8b4bd6ec8eb5f45f044cdcead73485a02d319b361d7fc78e7b478774bc5bba7f.png)
Preview
9.0
12-04SeekingAlphaPinnedNovo Nordisk Advances Alzheimer's Research and Plans December Launch of Ozempic in India
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/3466f90ffc5505b0c41a169bdc21b5787d46eec00713fca82e03aa078bad6842.png)
Preview
2.0
03:57 AMBenzingaWhat’s Behind the Surge in Viking Therapeutics Stock?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/7deaf73a82c7cf0d804805511c4d1cab3da120702b5fbd176d5f0e0246d0a17a.png)
Preview
9.0
01:01 AMMarketWatchWegovy Prices Are Decreasing, Yet They Remain 'Significantly Varied' and Confusing
Sign Up For More News
People Also Watch
FAQ
What is Novo Nordisk A/S (NVO) stock price today?
What is Novo Nordisk A/S (NVO)'s business?
What is the price predicton of NVO Stock?
What is Novo Nordisk A/S (NVO)'s revenue for the last quarter?
What is Novo Nordisk A/S (NVO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Novo Nordisk A/S (NVO)'s fundamentals?
How many employees does Novo Nordisk A/S (NVO). have?